Symptomatic: A Medical Mystery Podcast
Episode: A Reassessment of Prostate Cancer Treatment (Live from the 2024 ASCO Annual Meeting)
Host: Lauren Bright Pacheco
Guest: Dr. Mohammed Atik, Assistant Professor, Department of Medicine, University of Chicago Medicine
Introduction
In this compelling episode of Symptomatic, recorded live from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, host Lauren Bright Pacheco engages in an in-depth conversation with Dr. Mohammed Atik. Dr. Atik, a recognized expert in hematology and oncology with a focus on genitourinary cancers, brings his extensive knowledge and personal insights to the discussion on prostate cancer—a disease affecting one in eight men in their lifetime.
Understanding Prostate Cancer
Dr. Atik begins by breaking down the basics of prostate cancer, ensuring that listeners without a medical background can grasp the fundamental aspects of the disease.
What is the Prostate?
"The prostate is a gland in men, anatomically positioned behind the bladder and encompassing the tube that drains urine. It produces a protein called prostate-specific antigen (PSA), which is a component of seminal fluid" (04:14).
Why is Prostate Cancer So Common?
While the exact causes remain unclear, several risk factors are identified:
- Age: Approximately 70% of diagnoses occur in men over 65.
- Family History: Men with a first-degree relative diagnosed with prostate cancer have a doubled risk, which increases to fivefold with two first-degree relatives.
- Race: African American men in the United States have a higher incidence, though the role of diet remains inconclusive.
Dr. Atik draws parallels between prostate cancer in men and breast cancer in women, categorizing both as endocrine cancers due to their glandular nature (05:22).
Diagnosis and Screening
Timeline from Symptom Onset to Diagnosis:
Prostate cancer diagnosis can occur at various stages, often asymptomatically through screening or when symptoms become severe, such as bone pain or difficulty walking. Dr. Atik emphasizes the variability in symptom onset and the critical role of early detection (05:43).
Importance of Early Detection:
Early detection allows for monitoring before the cancer spreads or causes severe symptoms. However, early detection does not always mean immediate treatment. "Prostate cancer is risk stratified based on PSA levels, Gleason score, and clinical staging" (07:55).
Active Surveillance:
For low-risk cases, active surveillance is recommended, involving regular PSA checks, digital rectal exams, and periodic biopsies. This approach helps maintain quality of life by delaying invasive treatments until absolutely necessary. Dr. Atik clarifies, "Active surveillance doesn't mean you're not doing anything; you're strategically monitoring the disease" (09:48).
Treatment Options and Misconceptions
Misconceptions About Prostate Cancer:
A prevalent misunderstanding is the immediate need for aggressive treatment upon diagnosis. Dr. Atik addresses this by explaining that not all prostate cancers require immediate intervention. "Just because we can do something doesn't mean you have to" (10:36).
Emotional Impact of Diagnosis:
Delivering a cancer diagnosis is emotionally challenging for both patients and physicians. Dr. Atik discusses the importance of empathy and clear communication in helping patients navigate their emotions and treatment options. "You're on the same team with them, and we have a plan for you" (11:36).
Tailoring Treatment Plans:
Treatment is personalized based on risk stratification and life expectancy. Factors such as PSA levels, Gleason scores, and the extent of cancer influence the treatment approach. Dr. Atik emphasizes balancing treatment efficacy with quality of life, considering patients' tolerance for side effects and existing medical conditions (16:46).
Advancements in Treatment
Evolution of Treatment Options:
Reflecting on the past three decades, Dr. Atik highlights significant advancements:
- 30 Years Ago: Limited to hormone injections, androgen deprivation therapy, steroids, and mitoxantrone for symptom palliation.
- Today: Introduction of radio ligands, immune therapies, chemotherapy advancements, and targeted treatments like Pluvicto.
Radiopharmaceuticals:
Dr. Atik explains radiopharmaceuticals as therapies using radioactive particles to target cancer cells. Recent advancements include lutetium-based treatments, which have shown efficacy in managing metastatic castration-resistant prostate cancer (mCRPC) (24:31).
Innovative Therapies:
Emerging treatments such as antibody-drug conjugates and bispecific T-cell engagers represent the frontier of prostate cancer therapy. These targeted approaches aim to enhance the immune system's ability to fight cancer while minimizing side effects (28:05).
Sequencing Treatments:
Determining the optimal sequence of emerging treatments is crucial. Dr. Atik notes the importance of clinical trials in establishing effective treatment protocols and overcoming cancer's resistance mechanisms (30:06).
Emotional and Psychological Support
Support Systems:
Dr. Atik underscores the necessity of a comprehensive support team, including urologists, radiation oncologists, medical oncologists, nurses, pathologists, radiologists, and psychological support professionals. This multidisciplinary approach ensures that patients receive holistic care addressing both medical and emotional needs (35:53).
Addressing Masculinity and Emotional Well-being:
Prostate cancer can impact men's perceptions of masculinity and emotional health. Open discussions about treatment effects, such as testosterone reduction, and access to psychological counseling are vital in helping patients cope with their diagnosis and treatment (36:52).
Personal Reflections and Takeaways
Empathy in Practice:
Dr. Atik shares how treating prostate cancer has deepened his empathy and ability to connect with patients on a personal level. Understanding patients' fears and providing compassionate care are fundamental to his practice (38:14).
Key Takeaways for Patients:
- Active Surveillance is a Viable Option: Not all prostate cancers require immediate treatment, and monitoring can preserve quality of life.
- Stay Informed About Advancements: New treatments offer hope, but it's essential to work with knowledgeable physicians to determine the best options.
- Comprehensive Support is Essential: Emotional and psychological support plays a crucial role in managing the disease.
Advice for Healthcare Providers:
- Stay Updated with Advancements: Continuously educate themselves on the latest treatments to provide the best care.
- Effective Communication: Clearly explain risks, benefits, and treatment options to patients, fostering informed decision-making.
- Holistic Approach: Collaborate with a multidisciplinary team to address all aspects of patient health.
Conclusion
Dr. Mohammed Atik's insights provide a nuanced understanding of prostate cancer, emphasizing the importance of personalized treatment, early detection, and comprehensive support systems. His dedication to advancing prostate cancer treatment and improving patient outcomes underscores the evolving landscape of oncology. Listeners are encouraged to engage with their healthcare providers, stay informed about new therapies, and seek support to navigate the complexities of prostate cancer.
Notable Quotes:
- Dr. Mohammed Atik:
- "Prostate cancer is risk stratified based on PSA levels, Gleason score, and clinical staging." (07:55)
- "Active surveillance doesn't mean you're not doing anything; you're strategically monitoring the disease." (09:48)
- "Just because we can do something doesn't mean you have to." (10:36)
- "You're on the same team with them, and we have a plan for you." (11:36)
- "Prostate cancer can impact men's perceptions of masculinity and emotional health." (36:52)
- "Active Surveillance is a Viable Option: Not all prostate cancers require immediate treatment, and monitoring can preserve quality of life." (39:17)
These quotes encapsulate the core messages of the episode, highlighting the balance between proactive treatment and quality of life, as well as the empathetic approach necessary in oncology.